Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain ...

The U.S. Food and Drug Administration has declined to approve Capricor Therapeutics' cell therapy for a heart condition, the ...

Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company’s shares ...

The biometric process—run by Indian staff—involved standard fingerprinting and a photo. She stressed the importance of ...

The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's experimental gene therapy to treat ...

The recent federal announcement of a freeze on projects that help states use their Medicaid programs to suit the needs of ...

Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, ...

A CBS/YouGov poll released Sunday found Trump’s approval rating at 42%, with disapproval at 58%. That approval compares with ...

The National Identity Management Commission (NIMC) has clarified that the new price for correcting the date of birth (DOB) on ...